BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37438925)

  • 1. Is Likert better than PI-RADS at predicting prostate cancer on MRI and can a mathematical algorithm achieve similar results?
    Stevens W; Parchment-Smith C; Adiotomre E; Hulson O; Khan A; Melling P; Pierre S; Smith J
    Acta Radiol; 2023 Sep; 64(9):2659-2666. PubMed ID: 37438925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Making an art into a science: a mathematical "Likert tool" can change PI-RADS (v2) scores into Likert scores when reporting multiparametric MRI for prostate cancer.
    Stevens WM; Parchment-Smith C; Melling PP; Smith JT
    Acta Radiol; 2023 Mar; 64(3):1245-1254. PubMed ID: 35815700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Likert and PI-RADS version 2 MRI scoring systems for the detection of clinically significant prostate cancer.
    Zawaideh JP; Sala E; Pantelidou M; Shaida N; Koo B; Caglic I; Warren AY; Carmisciano L; Saeb-Parsy K; Gnanapragasam VJ; Kastner C; Barrett T
    Br J Radiol; 2020 Aug; 93(1112):20200298. PubMed ID: 32479105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Audit of cancer yields after prostate MRI using both the PI-RADS version 2 and Likert scoring systems.
    Sokhi HK; Wilson A; Pindoria N; McNamara C; Padhani AR; Meer Z; Pope A
    Clin Radiol; 2022 Jul; 77(7):541-547. PubMed ID: 35570157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.
    Brizmohun Appayya M; Sidhu HS; Dikaios N; Johnston EW; Simmons LA; Freeman A; Kirkham AP; Ahmed HU; Punwani S
    Br J Radiol; 2018 Feb; 91(1083):20170645. PubMed ID: 29189042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate Imaging Reporting and Data System and Likert Scoring System: Multiparametric MR Imaging Validation Study to Screen Patients for Initial Biopsy.
    Renard-Penna R; Mozer P; Cornud F; Barry-Delongchamps N; Bruguière E; Portalez D; Malavaud B
    Radiology; 2015 May; 275(2):458-68. PubMed ID: 25599415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla.
    Roethke MC; Kuru TH; Schultze S; Tichy D; Kopp-Schneider A; Fenchel M; Schlemmer HP; Hadaschik BA
    Eur Radiol; 2014 Feb; 24(2):344-52. PubMed ID: 24196383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
    Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
    World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Likert vs PI-RADS v2: a comparison of two radiological scoring systems for detection of clinically significant prostate cancer.
    Khoo CC; Eldred-Evans D; Peters M; Bertoncelli Tanaka M; Noureldin M; Miah S; Shah T; Connor MJ; Reddy D; Clark M; Lakhani A; Rockall A; Hosking-Jervis F; Cullen E; Arya M; Hrouda D; Qazi H; Winkler M; Tam H; Ahmed HU
    BJU Int; 2020 Jan; 125(1):49-55. PubMed ID: 31599113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement.
    Arcot R; Sekar S; Kotamarti S; Krischak M; Michael ZD; Foo WC; Huang J; Polascik TJ; Gupta RT
    Abdom Radiol (NY); 2022 Aug; 47(8):2917-2927. PubMed ID: 35674785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer.
    Chu CE; Cowan JE; Lonergan PE; Washington SL; Fasulo V; de la Calle CM; Shinohara K; Westphalen AC; Carroll PR
    Eur Urol Oncol; 2022 Oct; 5(5):537-543. PubMed ID: 33483265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective comparison of a fast 1.5-T biparametric with the 3.0-T multiparametric ESUR magnetic resonance imaging protocol as a triage test for men at risk of prostate cancer.
    Van Nieuwenhove S; Saussez TP; Thiry S; Trefois P; Annet L; Michoux N; Lecouvet F; Tombal B
    BJU Int; 2019 Mar; 123(3):411-420. PubMed ID: 30240059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.
    Sheridan AD; Nath SK; Syed JS; Aneja S; Sprenkle PC; Weinreb JC; Spektor M
    AJR Am J Roentgenol; 2018 Feb; 210(2):347-357. PubMed ID: 29112469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results.
    Tewes S; Hueper K; Hartung D; Imkamp F; Herrmann TR; Weidemann J; Renckly S; Kuczyk MA; Wacker F; Peters I
    World J Urol; 2015 Nov; 33(11):1707-14. PubMed ID: 25774003
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Davenport MS; Montgomery JS; Kunju LP; Siddiqui J; Shankar PR; Rajendiran T; Shao X; Lee E; Denton B; Barnett C; Piert M
    J Nucl Med; 2020 Mar; 61(3):337-343. PubMed ID: 31420496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
    Luzzago S; Musi G; Catellani M; Russo A; Di Trapani E; Mistretta FA; Bianchi R; Cozzi G; Conti A; Pricolo P; Ferro M; Matei DV; Mirone V; Petralia G; de Cobelli O
    Urol Int; 2018; 101(1):56-64. PubMed ID: 29734177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
    Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
    BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI-RADS) scoring in a transperineal prostate biopsy setting.
    Grey AD; Chana MS; Popert R; Wolfe K; Liyanage SH; Acher PL
    BJU Int; 2015 May; 115(5):728-35. PubMed ID: 25041307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.